2-[(3S,6S,9S,12S,21S,24S,27S,30S)-12,30-bis[(2S)-butan-2-yl]-24-(carboxymethyl)-9,27-bis(2-methylpropyl)-2,5,8,11,14,20,23,26,29,32-decaoxo-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31,34-dodecazatricyclo[32.2.2.216,19]tetracontan-6-yl]acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(3S,6S,9S,12S,21S,24S,27S,30S)-12,30-bis[(2S)-butan-2-yl]-24-(carboxymethyl)-9,27-bis(2-methylpropyl)-2,5,8,11,14,20,23,26,29,32-decaoxo-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31,34-dodecazatricyclo[32.2.2.216,19]tetracontan-6-yl]acetic acid
• 化学式: C₅₄H₉₂N₁₂O₁₄
• 分子量: 1133.4
• InChiKey: GTYDKLRMNNTPBO-YVRHMSMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  80
• 可旋转键数：
  14
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  355
• 氢给体数：
  10
• 氢受体数：
  16

文献信息

• TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR
  申请人：Progenity, Inc.

  公开号：US20200323772A1

  公开（公告）日：2020-10-15

  This disclosure features methods and compositions for treating inflammatory disorders or conditions that arise in a tissue originating from the endoderm using an immune modulator.